Pharma Journalist -

Citius Oncology, Inc. has announced a combined financing package of up to $36.5 million aimed at accelerating the commercialization of its cancer therapy LYMPHIR®. The funding includes…
Read More...

Latus Bio, Inc. has secured $97 million in Series A financing to accelerate the development of its gene therapy pipeline, marking a significant milestone for the early-stage biotech…
Read More...

The U.S. Food and Drug Administration has approved LANGLARA™ (insulin glargine-aldy), a biosimilar to Lantus® (insulin glargine), offering a potentially more affordable treatment option…
Read More...

UCB has announced a definitive agreement to acquire Candid Therapeutics in a deal valued at up to $2.2 billion, marking a significant expansion of its immunology pipeline and…
Read More...

The U.S. Food and Drug Administration has approved an expanded indication for Auvelity, allowing its use to treat agitation associated with dementia due to Alzheimer’s disease in…
Read More...

Novo Nordisk has announced the U.S. launch of Ozempic® (semaglutide) tablets, marking a significant expansion of its blockbuster diabetes franchise by introducing an oral version of the…
Read More...

Arrowhead Pharmaceuticals, Inc. has announced that Australia’s Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), marking the first authorized treatment in the…
Read More...

Gilead Sciences has finalized its acquisition of Arcellx, completing a deal valued at approximately $7.8 billion. The transaction marks a strategic expansion of Gilead’s oncology…
Read More...

Novartis has secured approval from the European Commission for its novel therapy Rhapsido, marking a significant advancement in the treatment of chronic spontaneous urticaria (CSU). The…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a move aimed at strengthening its oncology pipeline with a next-generation treatment for blood…
Read More...